ASTRAZENECA PHARMA Q2 FY27 ; STANDALONE NET PROFIT UP 14.96% AT ₹62.33 CR (YOY), UP 64.33% (QOQ)

REVENUE UP 30.41% AT ₹729.10 CR (YOY), UP 6.78% (QOQ) EBITDA UP 27.12% AT ₹95.57 CR (YOY), UP 95.28% (QOQ) MARGINS AT 13.11% VS 13.45% (YOY), 7.17% (QOQ)

AstraZeneca Pharma India Ltd

Open attachment

← Back to feed